CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Canada's Aurinia Q3 revenue rises 14% on LUPKYNIS sales

By Reuters News


Overview

  • Canada biopharma firm's Q3 total revenue rose 14% yr/yr, driven by LUPKYNIS sales

  • Diluted EPS for Q3 was flat yr/yr at $0.23

  • Company raised 2026 total revenue guidance and narrowed net product sales outlook


Outlook

  • Aurinia raises 2026 total revenue guidance to $325 mln-$330 mln from $315 mln-$325 mln

  • Company narrows 2026 net product sales guidance to $310 mln-$315 mln


Result Drivers

  • LUPKYNIS SALES - Co said higher sales of LUPKYNIS drove revenue growth

  • ROYALTY REVENUE - Increased license, collaboration and royalty revenue contributed to overall revenue growth

  • CLINICAL STUDY INITIATION - Co began new Phase 4 study combining LUPKYNIS with other therapies for lupus nephritis


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Revenue

$79.42 mln

Q3 EPS

$0.23

Q3 Net Income

$31.70 mln

Q3 Operating Expenses

$48.34 mln

Q3 Operating Income

$35.36 mln

Q3 Pretax Profit

$38.72 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc. is $18.00, about 4.6% above its October 29 closing price of $17.21

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Oct 29 - Merck Q3 profit beats on Keytruda demand

  • Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand

  • Oct 29 - Gilead Sciences Q3 adjusted EPS beats estimates on HIV growth; raises FY2026 sales outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.